Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...
The Financial Express20m
Lilly’s Zepbound outshines Wegovy in weight loss head-to-head trial
Wegovy was approved in the US as a treatment for heart disease in March, while Zepbound is expected to be given the green ...
The Root on MSN59mOpinion
[Opinion] Black Folks: Bust These 5 Ozempic, Wegovy Myths Because It Could Save Your Health
On Nov. 26, the Biden administration announced a plan to require Medicare and Medicaid to cover weight loss medications like ...